CURASIGHT A/S |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.96 DKK | +0.20% |
|
+9.45% | -43.89% |
| 04-16 | Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients | CI |
| 04-12 | Curasight A/S Announces Board Changes | CI |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 |
|---|---|---|---|
| Capitalization 1 | 353.1 | 198.1 | - |
| Enterprise Value (EV) 1 | 333 | 163.1 | 198.1 |
| P/E ratio | - | - | - |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | 4.61 x |
| EV / Revenue | - | - | 4.61 x |
| EV / EBITDA | -10.4 x | -2.55 x | -15.2 x |
| EV / FCF | -11.2 x | -2.55 x | - |
| FCF Yield | -8.97% | -39.2% | - |
| Price to Book | - | - | - |
| Nbr of stocks (in thousands) | 19,894 | 19,894 | - |
| Reference price 2 | 17.75 | 9.960 | 9.960 |
| Announcement Date | 22/02/24 | - | - |
1DKK in Million2
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | 43 |
| EBITDA 1 | - | -32.12 | -64 | -13 |
| EBIT 1 | - | -33.21 | -64 | -13 |
| Operating Margin | - | - | - | -30.23% |
| Earnings before Tax (EBT) | -19.49 | - | - | - |
| Net income | -18.35 | - | - | - |
| Net margin | - | - | - | - |
| EPS | - | - | - | - |
| Free Cash Flow 1 | - | -29.86 | -64 | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 23/02/23 | 22/02/24 | - | - |
1DKK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | - | 20.1 | 35 | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | -29.9 | -64 | - |
| ROE (net income / shareholders' equity) | - | -58.8% | -89% | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 23/02/23 | 22/02/24 | - | - |
1DKK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -43.89% | 28.61M | |
| +25.69% | 47.86B | |
| +46.90% | 41.42B | |
| -3.46% | 40.66B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- CURAS Stock
- Financials Curasight A/S
